Gossamer Bio, Inc. (GOSS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

8.19+0.19 (+2.37%)

As of 11:15AM EDT. Market open.

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

MACD

View all chart patterns

Performance Outlook

Previous Close	8.00
Open	7.73
Bid	8.11 x 1400
Ask	8.13 x 800
Day's Range	7.63 - 8.21
52 Week Range	7.63 - 16.79
Volume	148,740
Avg. Volume	620,070

Market Cap	621.7M
Beta (5Y Monthly)	1.23
PE Ratio (TTM)	N/A
EPS (TTM)	-3.45
Earnings Date	Feb 25, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	21.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Business Wire
Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the first quarter of 2021 and provided a corporate update.
- Orbital Energy Group Schedules First Quarter 2021 Financial Results Conference Call for Monday, May 17, 2021 at 8:30 am ET
  PR Newswire
- Callaway Golf Company Announces Record Financial Results For The First Quarter Of 2021; Topgolf Acquisition Exceeds Expectations; And Callaway Increases Financial Projections
  PR Newswire
Business Wire
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Luisa Salter-Cid, Ph.D., Gossamer’s Chief Scientific Officer, is resigning from Gossamer effective April 30, 2021. On that date, Laura Carter, Ph.D., currently Gossamer’s Senior Vice President, Research & Translational Biology, will be promoted to Chief Scientific Officer.
Business Wire
Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs. In this role, Ms. Peterson will continue to lead Gossamer’s Regulatory and Quality functions, tasked with strategizing and implementing global regulatory strategies for all clinical and pre-clinical programs, in addition to co-leading the Company’s CMC efforts. Ms. Peterson previously served as Senior Vice President, Regulatory & Quality after joining Gossamer in 2018.